Anti-diabetic and Antidyslipidemic Activities of Entandrophargma Cylindricum Extract on Streptozotocin-Induced Diabetic Rats

Abstract

This study aims to validate the anti-diabetic and antidyslipidemic activities of aqueous extract of Entandrophargma cylindricum stem on streptozotocin-induced diabetic rats. Thirty healthy male Albino rats (190 ± 10 g) were grouped into 6 groups of 5 each: group A (control) rats were not induced with diabetes; group B (diabetic treated with Metformin 100 mg/kg); group C (diabetic untreated); group D (diabetic treated with Entandrophargma cylindricum extract 50 mg/kg); group E (diabetic treated with Entandrophargma cylindricum extract 100 mg/kg) and group F (diabetic treated with Entandrophargma cylindricum extract 200 mg/kg). Fasting blood glucose concentration and glucose tolerance response increased after 7 days but was reversed near normal on day 14, day 21. Hexokinase activity significantly (p < 0.05) increase in the metformin and 200mg/kg bw. However, plasma high-density lipoprotein concentration, plasma insulin concentration, and hepatic glycogen level decreased in the untreated group, 50 and 100 mg/kg bw. Aqueous extract of E. cylindricum stem bark possesses significant anti-diabetic and antidyslipidemic activity in diabetic rats.